121 related articles for article (PubMed ID: 16334170)
21. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
Diepstra A; van Imhoff GW; Karim-Kos HE; van den Berg A; te Meerman GJ; Niens M; Nolte IM; Bastiaannet E; Schaapveld M; Vellenga E; Poppema S
J Clin Oncol; 2007 Jul; 25(21):3101-8. PubMed ID: 17536082
[TBL] [Abstract][Full Text] [Related]
22. A prognostic value of syndecan-1 in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2000; 20(6D):4905-7. PubMed ID: 11326638
[TBL] [Abstract][Full Text] [Related]
23. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
[TBL] [Abstract][Full Text] [Related]
24. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
[TBL] [Abstract][Full Text] [Related]
25. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma.
Salgami EV; Efstathiou SP; Vlachakis V; Sekara EV; Syrigos KN; Roussou PP
Haematologia (Budap); 2002; 32(4):377-87. PubMed ID: 12803112
[TBL] [Abstract][Full Text] [Related]
26. Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
Seidel C; Sundan A; Hjorth M; Turesson I; Dahl IM; Abildgaard N; Waage A; Borset M
Blood; 2000 Jan; 95(2):388-92. PubMed ID: 10627439
[TBL] [Abstract][Full Text] [Related]
27. Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations.
Anttonen A; Leppä S; Heikkilä P; Grenman R; Joensuu H
J Cancer Res Clin Oncol; 2006 Jul; 132(7):451-7. PubMed ID: 16557382
[TBL] [Abstract][Full Text] [Related]
28. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.
Tecchio C; Nadali G; Scapini P; Bonetto C; Visco C; Tamassia N; Vassilakopoulos TP; Pangalis GA; Calzetti F; Nardelli B; Roschke V; Gottardi M; Zampieri F; Gherlinzoni F; Facchetti F; Pizzolo G; Cassatella MA
Br J Haematol; 2007 Jun; 137(6):553-9. PubMed ID: 17539776
[TBL] [Abstract][Full Text] [Related]
29. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.
Dhodapkar MV; Kelly T; Theus A; Athota AB; Barlogie B; Sanderson RD
Br J Haematol; 1997 Nov; 99(2):368-71. PubMed ID: 9375756
[TBL] [Abstract][Full Text] [Related]
30. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
31. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.
Gharbaran R; Goy A; Tanaka T; Park J; Kim C; Hasan N; Vemulapalli S; Sarojini S; Tuluc M; Nalley K; Bhattacharyya P; Pecora A; Suh KS
J Hematol Oncol; 2013 Aug; 6():62. PubMed ID: 23988031
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy.
Anttonen A; Leppä S; Ruotsalainen T; Alfthan H; Mattson K; Joensuu H
Lung Cancer; 2003 Aug; 41(2):171-7. PubMed ID: 12871780
[TBL] [Abstract][Full Text] [Related]
35. Expression of BCL-6 protein and CD138/syndecan-1 as B-cell markers in Hodgkin's disease.
Carbone A; Gloghini A; Gaidano G
Int J Biol Markers; 1999; 14(3):144-8. PubMed ID: 10569135
[No Abstract] [Full Text] [Related]
36. [Relative study of soluble syndecan-1 and prognosis of patients with multiple myeloma].
Li X; Zhang X; Lu Z; Klein B
Zhonghua Xue Ye Xue Za Zhi; 2001 Jun; 22(6):303-5. PubMed ID: 11877089
[TBL] [Abstract][Full Text] [Related]
37. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
38. The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma.
Gupta S; Yeh S; Chami R; Punnett A; Chung C
Eur J Cancer; 2013 Oct; 49(15):3255-61. PubMed ID: 23791542
[TBL] [Abstract][Full Text] [Related]
39. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases.
Thompson LD; Fisher SI; Chu WS; Nelson A; Abbondanzo SL
Am J Clin Pathol; 2004 May; 121(5):727-38. PubMed ID: 15151213
[TBL] [Abstract][Full Text] [Related]
40. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
